Masimo Co. (NASDAQ:MASI) Shares Bought by RFG Advisory LLC

RFG Advisory LLC raised its position in Masimo Co. (NASDAQ:MASI - Free Report) by 73.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,780 shares of the medical equipment provider's stock after purchasing an additional 2,875 shares during the quarter. RFG Advisory LLC's holdings in Masimo were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp purchased a new stake in shares of Masimo during the fourth quarter worth $27,000. Blue Trust Inc. increased its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 71 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Masimo during the fourth quarter worth $46,000. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Stock Performance

MASI traded down $0.09 during trading on Monday, reaching $171.88. The company's stock had a trading volume of 787,546 shares, compared to its average volume of 645,921. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company's fifty day moving average price is $157.06 and its 200-day moving average price is $167.29. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of 118.54 and a beta of 1.19. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $372.00 million for the quarter, compared to analyst estimates of $367.79 million. During the same quarter in the prior year, the company earned $0.77 EPS. Masimo's revenue was down 24.5% on a year-over-year basis. On average, equities analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MASI shares. BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Raymond James dropped their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Wells Fargo & Company dropped their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $191.60.

Insider Activity at Masimo

In other news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Bilal Muhsin sold 10,000 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at $3,946,804.16. This represents a 29.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company's stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.